Semax: Neuropeptide Research and Cognitive Signalling

Semax is a synthetic heptapeptide analogue of the N-terminal fragment of adrenocorticotropic hormone ACTH(4-10). It was developed by researchers at the Institute of Molecular Genetics in Moscow and has been studied extensively in laboratory settings for its role in neuropeptide receptor research, cognitive signalling pathway studies, and neurotrophic factor biology.

Chemical and Molecular Data

ACTH(4-10) and Semax Design

Native ACTH(4-10) (Met-Glu-His-Phe-Arg-Trp-Gly) is the minimal active fragment of ACTH responsible for its non-steroidal neurological effects. Semax modifies this sequence by replacing the C-terminal Arg-Trp-Gly with Pro-Gly-Pro, which significantly increases the peptide's resistance to enzymatic degradation and extends its biological activity window in research settings.

The Pro-Gly-Pro extension is notable: Pro-Gly-Pro is itself a bioactive tripeptide studied for its role in leukocyte chemotaxis and as a product of collagen degradation, potentially contributing additional biological properties.

Neurotrophic Factor Research

One of the most studied aspects of Semax in laboratory settings is its relationship with brain-derived neurotrophic factor (BDNF) and its receptor TrkB. Research in rodent models has found associations between Semax administration and changes in BDNF expression in hippocampal and cortical tissues. BDNF plays roles in synaptic plasticity, neuronal survival, and long-term potentiation — all active areas of neuroscience research.

Research has also examined Semax's effects on nerve growth factor (NGF) expression and the expression of neurotrophin receptors, making it a tool compound of interest in neurotrophin biology research.

Dopaminergic and Serotonergic Research

Laboratory studies have examined Semax's effects on dopaminergic and serotonergic neurotransmission in rodent models. Research has investigated changes in dopamine and serotonin receptor expression following Semax treatment in various brain regions, including the striatum, prefrontal cortex, and hippocampus.

Neuroprotection Research Models

Semax has been studied as a tool compound in neuroprotection research models. Laboratory studies have examined its effects in models of ischaemia, oxidative stress, and excitotoxicity at the cellular level, investigating potential interactions with the nitric oxide system and inflammatory pathways relevant to neural tissue biology.

Research Applications

Semax is used in neuropeptide receptor pharmacology studies, BDNF and neurotrophin signalling research, dopaminergic and serotonergic neurotransmitter system studies, neuroprotection model research, and hippocampal plasticity research.

Semax vs Related Neuropeptide Research Tools

BDNF Pathway in Semax Research

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that signals through two receptors: TrkB (high affinity, mediates neuroplasticity and survival effects) and p75NTR (low affinity, mediates apoptotic effects). Laboratory research examining Semax has investigated changes in BDNF mRNA and protein expression in hippocampal and cortical tissues, with several rodent studies reporting increased BDNF expression following Semax administration.

The BDNF-TrkB signalling axis activates downstream pathways including MAPK/ERK (involved in synaptic plasticity), PI3K/Akt (cell survival), and PLCgamma/PKC (calcium-dependent signalling). Research examining Semax's effects on BDNF therefore connects to investigation of these downstream cascades and their roles in hippocampal long-term potentiation (LTP) — a cellular model of learning and memory.

Frequently Asked Questions

What is the Pro-Gly-Pro extension in Semax and does it have independent biological activity?
Pro-Gly-Pro is the C-terminal extension that distinguishes Semax from the native ACTH(4-10) sequence. This tripeptide is itself biologically active: it is a known chemotactic factor for leukocytes and is generated naturally as a collagen degradation product. Its inclusion in Semax increases the peptide's resistance to enzymatic degradation and may contribute additional biological properties to the research compound. Some published studies have examined Pro-Gly-Pro in isolation for comparison with full-length Semax activity.

How stable is Semax in biological media compared to native ACTH(4-10)?
Native ACTH(4-10) has a very short plasma half-life due to rapid cleavage by various proteases. The Pro-Gly-Pro C-terminal extension in Semax significantly improves resistance to carboxypeptidase degradation. The Met residue at position 1 remains a potential oxidation site — researchers working with Semax over extended incubation periods should be aware that Met oxidation can inactivate the peptide and should store lyophilised Semax protected from oxidising conditions.

For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.

Related research peptides: KPV | Kisspeptin-10 | BPC-157

View Semax product page

BDNF-TrkB Signalling Pathway

Semax research has focused substantially on BDNF (brain-derived neurotrophic factor) expression, placing it within the well-characterised BDNF-TrkB signalling system. BDNF is synthesised as a pre-pro-BDNF precursor, cleaved to pro-BDNF, and further processed to mature BDNF. Mature BDNF binds TrkB (NTRK2) with high affinity (Kd approximately 1 nM), activating receptor tyrosine kinase dimerisation and autophosphorylation.

Three major downstream cascades follow TrkB activation: PI3K/Akt (neuronal survival and growth cone dynamics), Ras/MAPK/ERK (synaptic plasticity and LTP-related gene transcription), and PLCgamma/IP3/calcium (calcium-dependent signalling and CREB activation). Published Semax research examining BDNF expression changes has used RT-PCR and ELISA to quantify mRNA and protein respectively, with hippocampal and cortical tissue or primary neuronal cultures as the standard model systems.

The BDNF-TrkB pathway is one of the most extensively validated targets in neuroscience — its established role in long-term potentiation (LTP), synaptic plasticity, hippocampal neurogenesis, and neuroprotection provides mechanistic context for interpreting Semax-related BDNF changes in research models.

Dopaminergic System Research

The dopaminergic component of Semax research examines its effects on catecholamine neurotransmission in striatal and prefrontal cortical models. Published studies have examined Semax in the context of dopamine transporter (DAT) expression and activity, dopamine receptor (D1R, D2R) sensitivity, and tyrosine hydroxylase (TH) expression — the rate-limiting enzyme of dopamine synthesis.

This dopaminergic research dimension connects to the parent ACTH(4-10) sequence: ACTH-derived peptides have established neurobiological effects on catecholamine systems in the central nervous system, and Semax as an ACTH(4-10) analogue inherits this research context. Research using 6-OHDA (6-hydroxydopamine) dopaminergic lesion models alongside Semax provides a paradigm for examining neuroprotective effects on dopaminergic neurons under conditions of selective catecholamine neurotoxicity.

Frequently Asked Questions

What is the significance of the Pro-Gly-Pro extension in Semax compared to native ACTH(4-10)?
Pro-Gly-Pro serves multiple functions. Carboxypeptidase protection: the terminal Pro residue is a poor carboxypeptidase substrate, and the tripeptide extension provides C-terminal protection beyond what the free Pro of ACTH(4-10) alone would provide. Pro-Gly-Pro is independently bioactive as a leukocyte chemotactic factor and ECM fragment, potentially adding immunomodulatory properties absent in native ACTH(4-10). Finally, Pro-Gly-Pro increases overall peptide length, improving aqueous solubility. The combination makes Semax a substantially more research-tractable tool than native ACTH(4-10).

How do Semax and Selank compare as neuropeptide research tools?
Both are Russian-developed heptapeptides with Pro-Gly-Pro C-terminal stability extensions, both are registered pharmaceuticals in Russia, and both have been studied for neuroprotective and cognitive effects. However, their primary mechanisms are distinct: Semax acts through ACTH-like mechanisms affecting BDNF, dopaminergic, and serotonergic systems; Selank acts through tuftsin-derived mechanisms affecting GABAergic, enkephalin, and immunomodulatory systems. Using both together (as in the Semax+Selank blend) provides complementary multi-system neurochemical research coverage.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide